




Instance: composition-en-13bb467fc3daebcc72e614a634466540
InstanceOf: CompositionUvEpi
Title: "Composition for isturisa Package Leaflet"
Description:  "Composition for isturisa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbc43190b4a4b05739c8cb47032566f64)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - isturisa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Isturisa is and what it is used for </li>
<li>What you need to know before you take Isturisa </li>
<li>How to take Isturisa </li>
<li>Possible side effects </li>
<li>How to store Isturisa </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What isturisa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What isturisa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Isturisa is 
Isturisa is a medicine that contains the active substance osilodrostat. </p>
<p>What Isturisa is used for 
Isturisa is used in adults to treat endogenous Cushing s syndrome, a condition in which the body 
produces too much of a hormone called cortisol. Too much cortisol may lead to a variety of symptoms 
such as weight gain (particularly around the waist), a moon-shaped face, bruising easily, irregular 
periods, excessive body and facial hair, and generally feeling weak, tired or unwell. </p>
<p>How Isturisa works 
Isturisa blocks the main enzyme that makes cortisol in the adrenal glands. The effect of this is to 
decrease the over-production of cortisol and improve the symptoms of endogenous Cushing s 
syndrome. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Isturisa:</p>
<ul>
<li>if you are allergic to osilodrostat or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Isturisa. </p>
<p>If any of the following apply to you, tell your doctor before taking Isturisa:</p>
<ul>
<li>if you have a heart disorder or a heart rhythm disorder, such as an irregular heartbeat, including 
a condition called prolonged QT syndrome (QT interval prolongation). </li>
<li>if you have a liver disease; your doctor may need to change your dose of Isturisa. </li>
</ul>
<p>Contact your doctor immediately if you have two or more of these symptoms during your treatment 
with Isturisa. This may indicate that you have adrenal insufficiency (low cortisol levels):</p>
<ul>
<li>weakness </li>
<li>light-headedness </li>
<li>tiredness </li>
<li>lack of appetite </li>
<li>nausea (feeling sick) </li>
<li>vomiting </li>
</ul>
<p>Tests before and during treatment 
Your doctor will test your blood and/or urine before you start treatment and regularly during 
treatment. This is to detect any possible abnormalities in your magnesium, calcium and potassium 
levels and also to measure the levels of cortisol. Depending on the results, your doctor may change 
your dose. </p>
<p>This medicine may have an unwanted effect (called QT prolongation) on the function of the heart. 
Your doctor will therefore also check for this effect by performing an electrocardiogram (ECG) before 
you start treatment and during treatment. </p>
<p>If your Cushing s syndrome is caused by a benign tumour (called adenoma) in the pituitary gland, 
your doctor may consider stopping your treatment if a pituitary scan shows that the adenoma has 
expanded into neighbouring regions. </p>
<p>Children and adolescents 
This medicine is not recommended for patients aged under 18 years. This is because there is a lack of 
data in these patients. </p>
<p>Other medicines and Isturisa 
Tell your doctor if you are taking, have recently taken or might take any other medicines. It is 
particularly important that you mention any of the following medicines:</p>
<ul>
<li>medicines that may have an unwanted effect (called QT prolongation) on the function of the 
heart. These include medicines used for abnormal heart rhythm such as quinidine, sotalol and 
amiodarone; medicines used for allergies (antihistamines); antidepressants such as amitriptyline 
and drugs for mental health disorders (antipsychotics); antibiotics, including the following 
types: macrolides, fluoroquinolones or imidazole; and other medicines for Cushing s disease 
(pasireotide, ketoconazole) </li>
<li>theophylline (used to treat breathing problems) or tizanidine (used to treat muscle pain and 
muscle cramps) </li>
</ul>
<p>Pregnancy and breast-feeding 
This medicine should not be used during pregnancy or breast-feeding, unless your doctor has advised 
you to do so. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have 
a baby, ask your doctor for advice before taking this medicine. </p>
<p>Contraception 
Women who could become pregnant should use an effective method of contraception during treatment 
and for at least one week after the last dose. Ask your doctor about the need for contraception before 
you start taking Isturisa. </p>
<p>Driving and using machines 
Dizziness and tiredness may occur during treatment with Isturisa. Do not drive or operate machines if 
you get these symptoms. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The usual starting dose is two 1 mg tablets twice a day (about every 12 hours). Patients of Asian 
ancestry and patients with liver disease may need a lower starting dose (one 1 mg tablet twice a day). </p>
<p>After you have started treatment, your doctor may change your dose. This will depend on how you 
respond to the treatment. The highest recommended dose is 30 mg twice a day. </p>
<p>Isturisa tablets are taken by mouth and can be taken with or without food. </p>
<p>If you take more Isturisa than you should 
If you have taken more Isturisa than you should and you feel unwell (for example if you feel weak, 
light-headed, tired or sick, or if you have to vomit), or if someone else accidentally takes your 
medicine, contact a doctor or hospital for advice immediately. Medical treatment may be needed. </p>
<p>If you forget to take Isturisa 
Do not take a double dose to make up for a forgotten dose. Instead, just wait until it is time for your 
next dose and take that at the scheduled time. </p>
<p>If you stop taking Isturisa 
Do not stop taking Isturisa unless your doctor tells you to. If you stop your treatment with Isturisa, 
your symptoms may come back. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Some side effects may be serious. Please take particular note of the following:</p>
<ul>
<li>Tell your doctor immediately if you experience a heart disorder or heart rhythm disorder, such 
as a fast and irregular heartbeat, even when you are at rest, heart palpitations, blackouts or 
fainting (this could be a sign of a condition called QT prolongation, a side effect that may affect 
up to 1 in 10 people). </li>
<li>Tell your doctor immediately if you have two or more of these symptoms: weakness, 
light-headedness, tiredness (fatigue), lack of appetite, nausea (feeling sick), vomiting. This may 
indicate that you have adrenal insufficiency (low cortisol levels), a side effect that may affect 
more than 1 in 10 people. Adrenal insufficiency occurs when Isturisa lowers the amount of 
cortisol too much. It is more likely to occur during periods of increased stress. Your doctor will 
correct this by using a hormone medicine or by adjusting the dose of Isturisa. </li>
</ul>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>vomiting </li>
<li>nausea (feeling sick) </li>
<li>diarrhoea </li>
<li>abdominal pain </li>
<li>tiredness (fatigue) </li>
<li>build-up of fluid leading to swelling (oedema), particularly of your ankles </li>
<li>abnormal blood tests (increased levels of testosterone, increased levels of adrenocorticotrophic 
hormone, also known as ACTH, low levels of potassium) </li>
<li>decreased appetite </li>
<li>dizziness </li>
<li>myalgia (muscle pain) </li>
<li>
<p>arthralgia (joint pain) </p>
</li>
<li>
<p>headache </p>
</li>
<li>rash </li>
<li>low blood pressure (hypotension) </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>fast heartbeat (tachycardia) </li>
<li>general feeling of being unwell (malaise) </li>
<li>abnormal results of liver function tests </li>
<li>fainting (syncope) </li>
<li>excessive facial or body hair growth (hirsutism) </li>
<li>acne </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Do not store above 25 C. </p>
<p>Store in the original package in order to protect from moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Isturisa contains 
- The active substance is osilodrostat. Each film-coated tablet contains 1 mg osilodrostat, 5 mg 
osilodrostat or 10 mg osilodrostat. 
- The other ingredients are:</p>
<ul>
<li>In the tablet core: microcrystalline cellulose, mannitol, croscarmellose sodium, 
magnesium stearate, colloidal anhydrous silica. </li>
<li>In the film coating: hypromellose, titanium dioxide (E171), iron oxides (E172, see 
below), macrogol and talc. </li>
<li>Isturisa 1 mg film-coated tablets contain iron oxide yellow and iron oxide red. </li>
<li>Isturisa 5 mg film-coated tablets contain iron oxide yellow. </li>
<li>Isturisa 10 mg film-coated tablets contain iron oxide yellow, iron oxide red and 
iron oxide black. </li>
</ul>
<p>What Isturisa looks like and contents of the pack 
Isturisa is available in packs containing 60 film-coated tablets. </p>
<p>The 1 mg tablets are pale yellow, round, unscored and debossed with  1  on one side. The approximate 
diameter is 6.1 mm. </p>
<p>The 5 mg tablets are yellow, round, unscored and debossed with  5  on one side. The approximate 
diameter is 7.1 mm. </p>
<p>The 10 mg tablets are pale orange brown, round, unscored and debossed with  10  on one side. The 
approximate diameter is 9.1 mm. </p>
<p>Marketing Authorisation Holder 
Recordati Rare Diseases 
Immeuble Le Wilson 
70 avenue du G n ral de Gaulle 
92800 Puteaux 
France </p>
<p>Manufacturer 
Millmount Healthcare Ltd                 <br />
Block 7, City North 
Business Campus, Stamullen,      <br />
Co. Meath, K32 YD60,<br />
Ireland </p>
<p>Recordati Rare Diseases 
Immeuble Le Wilson 
70 avenue du G n ral de Gaulle 
92800 Puteaux 
France </p>
<p>Recordati Rare Diseases 
Eco River Parc 
30 rue des Peupliers 
92000 Nanterre 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Recordati 
T l/Tel: +32 2 46101 Lietuva 
Recordati AB. 
Tel: + 46 8 545 80  vedija </p>
<p>Recordati Rare Diseases 
Te .: +33 (0)1 47 73 64   </p>
<p>Luxembourg/Luxemburg 
Recordati 
T l/Tel: +32 2 46101 Belgique/Belgien 
 esk  republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francie </p>
<p>Magyarorsz g 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franciaorsz g 
Danmark 
Recordati AB. 
Tlf: + 46 8 545 80 Sverige </p>
<p>Malta 
Recordati Rare Diseases 
Tel: +33 1 47 73 64 Franza 
Deutschland 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 </p>
<p>Nederland 
Recordati 
Tel: +32 2 46101 Belgi  </p>
<p>Eesti 
Recordati AB. 
Tel: + 46 8 545 80 Rootsi </p>
<p>Norge 
Recordati AB. 
Tlf: + 46 8 545 80 Sverige </p>
<p>Recordati Hellas 
 : +30 210 6773 sterreich 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 
Deutschland </p>
<p>Espa a 
Recordati Rare Diseases Spain S.L.U. 
Tel: + 34 91 659 28 Polska 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francja </p>
<p>France 
Recordati Rare Diseases 
T l: +33 (0)1 47 73 64 Portugal 
Jaba Recordati S.A. 
Tel: +351 21 432 95 Hrvatska 
Recordati Rare Diseases 
T l: +33 (0)1 47 73 64 Francuska </p>
<p>Rom nia 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Fran a 
Ireland 
Recordati Rare Diseases 
T l: +33 (0)1 47 73 64 France </p>
<p>Slovenija 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francija 
 sland 
Recordati AB. 
Simi: + 46 8 545 80 Sv j  </p>
<p>Slovensk  republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franc zsko 
Italia 
Recordati Rare Diseases Italy Srl 
Tel: +39 02 487 87 Suomi/Finland 
Recordati AB. 
Puh/Tel : +46 8 545 80 Sverige </p>
<p>Recordati Rare Diseases 
  : +33 1 47 73 64   </p>
<p>Sverige 
Recordati AB. 
Tel : +46 8 545 80 Latvija 
Recordati AB. 
Tel: + 46 8 545 80 Zviedrija 
United Kingdom (Northern Ireland) 
Recordati Rare Diseases UK Ltd. 
Tel: +44 (0)1491 414This leaflet was last revised in  </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-13bb467fc3daebcc72e614a634466540
InstanceOf: CompositionUvEpi
Title: "Composition for isturisa Package Leaflet"
Description:  "Composition for isturisa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpbc43190b4a4b05739c8cb47032566f64)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - isturisa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Isturisa 
3. Sådan skal du tage Isturisa 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What isturisa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What isturisa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Isturisa er 
Isturisa er et lægemiddel, der indeholder det aktive stof osilodrostat. </p>
<p>Hvad Isturisa anvendes til 
Isturisa anvendes til behandling af voksne med endogent Cushings syndrom, som er en tilstand, hvor 
kroppen danner for meget af et hormon, der kaldes kortisol. For meget kortisol kan give forskellige 
symptomer, som fx vægtstigning (især omkring taljen), et måneformet ansigt, lettere ved at få blå 
mærker, uregelmæssig menstruation, øget hårvækst på kroppen og i ansigtet og almen svaghed, træthed 
eller utilpashed. </p>
<p>Hvordan Isturisa virker 
Isturisa blokerer det enzym, der hovedsagelig laver kortisol i binyrerne. Dette gør, at overproduktionen af 
kortisol bremses, og at symptomerne på endogent Cushings syndrom bliver mindre. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Isturisa 
- hvis du er allergisk over for osilodrostat eller et af de øvrige indholdsstoffer i Isturisa (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Isturisa. </p>
<p>Hvis noget af det følgende gælder for dig, skal du fortælle det til lægen, før du begynder at tage Isturisa:</p>
<ul>
<li>hvis du har et hjerteproblem eller en hjerterytmeforstyrrelse, fx uregelmæssige hjerteslag, herunder 
en tilstand, der kaldes langt QT-syndrom (forlænget QT-interval). </li>
<li>hvis du har en leversygdom; det kan være, at lægen bliver nødt til at ændre din dosis af Isturisa. </li>
</ul>
<p>Kontakt omgående din læge, hvis du får to eller flere af disse symptomer under din behandling med 
Isturisa. Dette kan være tegn på, at du har binyrebarkinsufficiens (lavt kortisolniveau):</p>
<ul>
<li>svaghed </li>
<li>svimmelhed </li>
<li>træthed </li>
<li>manglende appetit </li>
<li>kvalme </li>
<li>opkastning </li>
</ul>
<p>Undersøgelser før og under behandlingen 
Lægen vil undersøge dit blod og/eller din urin, før du starter på behandling og regelmæssigt under 
behandlingen. Dette gøres for at holde øje med mulige afvigelser i dine niveauer af magnesium, calcium 
og kalium og også for at måle niveauet af kortisol. Lægen kan ændre din dosis alt efter resultaterne. </p>
<p>Dette lægemiddel kan have en uønsket virkning (kaldet QT-forlængelse) på hjertets funktion. Din læge 
vil derfor også tjekke dig for dette ved at lave et elektrokardiogram (EKG), før du starter på behandling 
og under behandlingen. </p>
<p>Hvis dit Cushings syndrom er forårsaget af en godartet tumor (kaldet adenom) i hypofysen, kan din læge 
overveje at stoppe din behandling, hvis en scanning af hypofysen viser, at adenomet har spredt sig til de 
omkringliggende områder.  </p>
<p>Børn og unge 
Dette lægemiddel anbefales ikke til patienter under 18 år. Grunden er, at der mangler data om disse 
patienter. </p>
<p>Brug af andre lægemidler sammen med Isturisa 
Fortæl lægen, hvis du tager andre lægemidler, for nylig har taget andre lægemidler eller planlægger at 
tage andre lægemidler. Det er især vigtigt, at du nævner følgende lægemidler:</p>
<ul>
<li>lægemidler, der kan have en uønsket virkning (kaldet QT-forlængelse) på hjertets funktion. Dette 
omfatter lægemidler, som anvendes til behandling af unormal hjerterytme, som fx kinidin, sotalol 
og amiodaron; lægemidler, der anvendes til behandling af allergi (antihistaminer); antidepressiva, 
som fx amitriptylin og lægemidler til behandling af psykiske lidelser (antipsykotika); antibiotika, 
herunder følgende typer: makrolider, fluorquinoloner eller imidazol, og andre lægemidler til 
behandling af Cushings sygdom (pasireotid, ketoconazol) </li>
<li>theophyllin (anvendes til behandling af vejrtrækningsproblemer) eller tizanidin (anvendes til 
behandling af muskelsmerter og muskelkramper) </li>
</ul>
<p>Graviditet og amning 
Du må ikke tage dette lægemiddel under graviditet eller amning, medmindre din læge har anbefalet dig at 
gøre det. Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive 
gravid, skal du spørge din læge til råds, før du tager dette lægemiddel. </p>
<p>Prævention 
Kvinder, der kan blive gravide, skal anvende en sikker præventionsmetode under behandlingen og i 
mindst én uge efter den sidste dosis. Spørg din læge om behovet for prævention, før du starter med at 
tage Isturisa. </p>
<p>Trafik- og arbejdssikkerhed 
Svimmelhed og træthed kan forekomme under behandlingen med Isturisa. Du må ikke føre motorkøretøj 
eller betjene maskiner, hvis du får disse symptomer. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den sædvanlige startdosis er to 1 mg tabletter to gange dagligt (ca. hver 12. time). Patienter af asiatisk 
oprindelse og patienter med leversygdom kan have behov for en lavere startdosis (en 1 mg tablet to 
gange dagligt). </p>
<p>Lægen kan ændre din dosis, efter at du er startet på behandlingen. Dette vil afhænge af, hvordan du 
reagerer på behandlingen. Den højeste anbefalede dosis er 30 mg to gange dagligt. </p>
<p>Isturisa-tabletter tages gennem munden og kan tages sammen med eller uden mad. </p>
<p>Hvis du har taget for meget Isturisa 
Hvis du har taget for meget Isturisa og du føler dig utilpas (fx hvis du føler dig svag, svimmel, træt, har 
kvalme eller skal kaste op), eller hvis en anden ved et uheld tager dit lægemiddel, skal du omgående 
kontakte en læge eller et hospital for at blive rådgivet. Lægebehandling kan være nødvendig. </p>
<p>Hvis du har glemt at tage Isturisa 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Vent i stedet, til det er tid til din 
næste dosis, og tag så den dosis på det planlagte tidspunkt. </p>
<p>Hvis du holder op med at tage Isturisa 
Stop ikke med at tage Isturisa, medmindre din læge har bedt dig om det. Hvis du stopper din behandling 
med Isturisa, kan dine symptomer komme igen. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige. Vær særligt opmærksom på følgende:</p>
<ul>
<li>Fortæl det straks til din læge, hvis du oplever et hjerteproblem eller en hjerterytmeforstyrrelse, 
som fx hurtig og uregelmæssige hjerteslag selv når du er i ro, hjertebanken, bevidsthedstab eller 
besvimelse (det kan være tegn på en tilstand, der kaldes QT-forlængelse, en bivirkning der kan 
forekomme hos op til 1 ud af 10 personer). </li>
<li>Fortæl det straks til din læge, hvis du får to eller flere af disse symptomer: svaghed, svimmelhed, 
træthed, manglende appetit, kvalme, opkastning. Det kan være tegn på, at du har 
binyrebarkinsufficiens (lavt kortisolniveau), en bivirkning der kan forekomme hos flere end 1 ud 
af 10 personer. Binyrebarkinsufficiens forekommer, når mængden af kortisol nedsættes for meget 
af Isturisa. Det vil mest sandsynligt at opstå under perioder med øget stres. Din læge vil rette op på 
dette ved at anvende et hormonelt lægemiddel eller ved at justere dosis af Isturisa. </li>
</ul>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>opkastning </li>
<li>kvalme </li>
<li>diarré </li>
<li>mavesmerter </li>
<li>træthed </li>
<li>væskeophobning, hvilket giver hævelse (ødem), særligt omkring anklerne </li>
<li>unormale blodtal (øget niveau af testosteron, øget niveau af adrenokortikotropt hormon, også 
kaldet ACTH, lavt niveau af kalium) </li>
<li>nedsat appetit </li>
<li>svimmelhed </li>
<li>hurtig puls (takykardi) </li>
<li>myalgi (muskelsmerte) </li>
<li>artralgi (ledsmerte) </li>
<li>hovedpine </li>
<li>udslæt </li>
<li>lavt blodtryk (hypotension) </li>
<li>øget hårvækst i ansigt eller på krop (hirsutisme) </li>
<li>akne </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>generel følelse af utilpashed </li>
<li>unormale levertal </li>
<li>besvimelse (synkope) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. 
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af 
dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store isturisa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store isturisa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og på blisteren efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 25°C. </p>
<p>Opbevares i den originale pakning for at beskytte mod fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du ikke 
smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Isturisa indeholder:</p>
<ul>
<li>Aktivt stof: osilodrostat. Hver filmovertrukket tablet indeholder 1 mg osilodrostat, 5 mg 
osilodrostat eller 10 mg osilodrostat. </li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>Tabletkerne: mikrokrystallinsk cellulose, mannitol, croscarmellosenatrium, 
magnesiumstearat, kolloid vandfri silica. </p>
</li>
<li>Filmovertræk: hypromellose, titandioxid (E171), jernoxider (E172, se nedenfor), macrogol 
og talcum. </li>
<li>Isturisa 1 mg filmovertrukne tabletter indeholder gul jernoxid og rød jernoxid. </li>
<li>Isturisa 5 mg filmovertrukne tabletter indeholder gul jernoxid. </li>
<li>Isturisa 10 mg filmovertrukne tabletter indeholder gul jernoxid, rød jernoxid og sort 
jernoxid. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Isturisa fås i pakninger, der indeholder 60 filmovertrukne tabletter. </p>
<p>1 mg-tabletterne er lysegule, runde, uden riller og præget med “1" på den ene side . Diameteren er ca. 
6,1 mm. </p>
<p>5 mg-tabletterne er gule, runde, uden riller og præget med “5" på den ene side . Diameteren er ca. 
7,1 mm. </p>
<p>10 mg-tabletterne er lyse orangebrune, runde, uden riller og præget med “10" på den ene side . 
Diameteren er ca. 9,1 mm. </p>
<p>Indehaver af markedsføringstilladelsen 
Recordati Rare Diseases 
Immeuble Le Wilson 
70 avenue du Général de Gaulle 
92800 Puteaux 
France </p>
<p>Fremstiller 
Millmount Healthcare Ltd<br />
Block 7, City North<br />
Business Campus, Stamullen,<br />
Co. Meath, K32 YD60, 
Irland </p>
<p>Recordati Rare Diseases 
Immeuble Le Wilson 
70 avenue du Général de Gaulle 
92800 Puteaux 
France </p>
<p>Recordati Rare Diseases 
Eco River Parc 
30 rue des Peupliers 
92000 Nanterre 
France </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Recordati 
Tél/Tel: +32 2 46101<br />
Lietuva 
Recordati AB. 
Tel: + 46 8 545 80 Švedija </p>
<p>България 
Recordati Rare Diseases 
Teл.: +33 (0)1 47 73 64 Франция </p>
<p>Luxembourg/Luxemburg 
Recordati 
Tél/Tel: +32 2 46101 Belgique/Belgien 
Česká republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francie </p>
<p>Magyarország 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franciaország 
Danmark 
Recordati AB. 
Tlf.: + 46 8 545 80 Sverige </p>
<p>Malta 
Recordati Rare Diseases 
Tel: +33 1 47 73 64 Franza 
Deutschland 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 </p>
<p>Nederland 
Recordati 
Tel: +32 2 46101 België </p>
<p>Eesti 
Recordati AB. 
Tel: + 46 8 545 80 Rootsi </p>
<p>Norge 
Recordati AB. 
Tlf: + 46 8 545 80 Sverige 
Ελλάδα 
Recordati Hellas 
Τηλ: +30 210 6773 
Österreich 
Recordati Rare Diseases Germany GmbH 
Tel: +49 731 140 554 0 
Deutschland </p>
<p>España 
Recordati Rare Diseases Spain S.L.U. 
Tel: + 34 91 659 28<br />
Polska 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francja </p>
<p>France 
Recordati Rare Diseases 
Tél: +33 (0)1 47 73 64<br />
Portugal 
Jaba Recordati S.A. 
Tel: +351 21 432 95 Hrvatska 
Recordati Rare Diseases 
Tél: +33 (0)1 47 73 64 Francuska </p>
<p>România 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Franţa 
Ireland 
Recordati Rare Diseases 
Tél: +33 (0)1 47 73 64 France </p>
<p>Slovenija 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francija 
Ísland 
Recordati AB. 
Simi: + 46 8 545 80 Svíþjóð </p>
<p>Slovenská republika 
Recordati Rare Diseases 
Tel: +33 (0)1 47 73 64 Francúzsko 
Italia 
Recordati Rare Diseases Italy Srl 
Tel: +39 02 487 87<br />
Suomi/Finland 
Recordati AB. 
Puh/Tel : +46 8 545 80 Sverige </p>
<p>Κύπρος 
Recordati Rare Diseases 
Τηλ : +33 1 47 73 64 Γαλλία </p>
<p>Sverige 
Recordati AB. 
Tel : +46 8 545 80 Latvija 
Recordati AB. 
Tel: + 46 8 545 80 Zviedrija 
United Kingdom (Northern Ireland) 
Recordati Rare Diseases UK Ltd. 
Tel: +44 (0)1491 414 
Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-13bb467fc3daebcc72e614a634466540
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for isturisa Package Leaflet for language en"
Description: "ePI document Bundle for isturisa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-13bb467fc3daebcc72e614a634466540"
* entry[0].resource = composition-en-13bb467fc3daebcc72e614a634466540

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp13bb467fc3daebcc72e614a634466540"
* entry[=].resource = mp13bb467fc3daebcc72e614a634466540
                            
                    
Instance: bundlepackageleaflet-da-13bb467fc3daebcc72e614a634466540
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for isturisa Package Leaflet for language da"
Description: "ePI document Bundle for isturisa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-13bb467fc3daebcc72e614a634466540"
* entry[0].resource = composition-da-13bb467fc3daebcc72e614a634466540

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp13bb467fc3daebcc72e614a634466540"
* entry[=].resource = mp13bb467fc3daebcc72e614a634466540
                            
                    



Instance: mp13bb467fc3daebcc72e614a634466540
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Isturisa 1 mg film-coated tablets"
Description: "Isturisa 1 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Isturisa 1 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Isturisa 1 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 13bb467fc3daebcc72e614a634466540ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "isturisa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with isturisa"

* subject = Reference(mpbc43190b4a4b05739c8cb47032566f64)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#isturisa "isturisa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-13bb467fc3daebcc72e614a634466540) // isturisa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-13bb467fc3daebcc72e614a634466540) // isturisa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-13bb467fc3daebcc72e614a634466540
InstanceOf: List

* insert 13bb467fc3daebcc72e614a634466540ListRuleset
    